a Department of Radiation Oncology , Erasmus MC Cancer Institute , Rotterdam , Netherlands.
b Department of Otorhinolaryngology-Head and neck surgery , Erasmus MC Cancer Institute , Rotterdam , Netherlands.
Int J Hyperthermia. 2018 Nov;34(7):994-1001. doi: 10.1080/02656736.2018.1454610. Epub 2018 May 11.
Radiotherapy (RT) treatment of locally-advanced and recurrent head and neck carcinoma (HNC) results in disappointing outcomes. Combination of RT with cisplatin or cetuximab improves survival but the increased toxicity and patient's comorbidity warrant the need for a less-toxic radiosensitizer. Stimulated by several randomized studies demonstrating the radio-sensitizing effect of hyperthermia, we developed the HYPERcollar. Here, we report early experience and toxicity in patients with advanced HNC.
119 hyperthermia treatments given to 27 patients were analyzed. Hyperthermia was applied once a week by the HYPERcollar aimed at achieving 39-43 °C in the target area, up to patients' tolerance. Pre-treatment planning was used to optimize treatment settings. When possible, invasive thermometry catheters were placed.
Mean power applied during the 119 hyperthermia treatments ranged from 120 to 1007 W (median 543 W). 15 (13%) hyperthermia treatments were not fully completed due to: pain allocated to hyperthermia (6/15), dyspnea from sticky saliva associated with irradiation (2/15) and unknown reasons (7/15). No severe complications or enhanced thermal or mucosal toxicities were observed. Excluding post-operative treatment, response rates after 3 months were 46% (complete) and 7% (partial).
Hyperthermia with the HYPERcollar proved to be safe and feasible with good compliance and promising outcome.
局部晚期和复发性头颈部癌（HNC）的放射治疗（RT）结果令人失望。RT 联合顺铂或西妥昔单抗可提高生存率，但增加的毒性和患者的合并症需要一种毒性较小的放射增敏剂。受几项随机研究表明热疗具有放射增敏作用的刺激，我们开发了 HYPERCOLLAR。在此，我们报告了晚期 HNC 患者的早期经验和毒性。
对 27 名患者的 119 次热疗进行了分析。HYPERCOLLAR 每周应用一次，旨在使靶区达到 39-43°C，达到患者的耐受程度。使用预处理计划来优化治疗设置。在可能的情况下，放置侵入性测温导管。
119 次热疗中平均应用功率范围为 120-1007W（中位数 543W）。由于以下原因，有 15（13%）次热疗未完全完成：分配给热疗的疼痛（6/15）、与放疗相关的粘性唾液引起的呼吸困难（2/15）和未知原因（7/15）。未观察到严重并发症或增强的热或粘膜毒性。不包括术后治疗，3 个月后的反应率分别为 46%（完全）和 7%（部分）。
HYPERCOLLAR 热疗安全可行，依从性好，疗效有希望。
